Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT)

被引：0
|
作者：
Grote, T
Hajdenberg, J
Cartmell, A
Ferguson, S
Ginkel, A
Gallagher, S
Charu, V
机构：
[1] Piedmont Hematol Oncol, Winston Salem, NC USA
[2] Pasco Pinellas Canc Ctr, Tarpon Springs, FL USA
[3] Comprehens Blood & Canc Inst, Bakersfield, CA USA
[4] Cooper Green Hosp, Birmingham, AL USA
[5] MGI Pharma, Bloomington, MN USA
[6] Pacific Canc Med Ctr, Anaheim, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8262
引用
收藏
页码：794S / 794S
页数：1
相关论文
共 50 条
  • [1] Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Boccia, R. V.
    Gonzalez, E. F.
    Pluzanska, A. G.
    Clerici, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy-induced nausea & vomiting after emetogenic chemotherapy
    Grote, T.
    Hajdenberg, J.
    Cartmell, A.
    Ferguson, S.
    Gallagher, S.
    Piraccini, G.
    Charu, V.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 371 - 372
  • [3] THE EFFICACY OF TRIPLET ANTIEMETIC THERAPY FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN LUNG CANCER PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY: PALONOSETRON (PALO), APREPITANT (APR), AND DEXAMETHASONE (DEX)
    Yoshizawa, H.
    Sato, K.
    Makino, M.
    Kobayashi, O.
    Tanaka, H.
    Miura, S.
    Watanabe, S.
    Tanaka, J.
    Kagamu, H.
    Ichiei, N.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 509 - 509
  • [4] Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting
    Kwon, J. H.
    Kang, J-H.
    Lee, Y-G.
    Park, K. U.
    An, H. J.
    Sohn, J.
    Seol, Y. M.
    Lee, H.
    Yun, H-J.
    Ahn, J. S.
    Kim, H. J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
    Hesketh, Paul Joseph
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Alyasova, Anna
    Drobner, Igor
    Gralla, Richard J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Palonosetron (PALO) plus dexamethasone (DEX) for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving multiple-day cisplatin CT for germ cell cancer.
    Brames, M. J.
    Roth, B. J.
    Dreicer, R.
    Bubalo, J.
    Nichols, C.
    Cullen, M. T.
    Degroot, T.
    Einhorn, L. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 494S - 494S
  • [7] Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Moderately Emetogenic (MEC) Chemotherapy in Patients with Breast Cancer
    Webb, T.
    Hardwick, J.
    Carides, A. D.
    Street, J. C.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 575S - 576S
  • [8] Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy
    Gao, H. F.
    Liang, Y.
    Zhou, N. N.
    Zhang, D. S.
    Wu, H. Y.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (01) : 73 - 76
  • [9] Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy
    Molassiotis, Alex
    Nguyen, Allison Martin
    Rittenberg, Cynthia N.
    Makalinao, Alex
    Carides, Alexandra
    [J]. FUTURE ONCOLOGY, 2013, 9 (10) : 1443 - 1450
  • [10] Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
    Kang, Jin Hyoung
    Kwon, Jung Hye
    Lee, Yun-Gyoo
    Park, Keon Uk
    An, Ho Jung
    Sohn, Joohyuk
    Seol, Young Mi
    Lee, Hyunwoo
    Yun, Hwan-Jung
    Ahn, Jin Seok
    Yang, Ji Hyun
    Song, Hunho
    Koo, Dong-Hoe
    Kim, Jin Young
    Kim, Gun Min
    Kim, Hwa Jung
    [J]. CANCER RESEARCH AND TREATMENT, 2020, 52 (03): : 907 - 916
12345